The Swedish Medical Products Agency has approved a new treatment arm with Remygen® and Alprazolam in Phase I/II ReGenerate-1 clinical trial led by Uppsala University Hospital and path-breaking investigator Professor Per-Ola Carlsson. The Study: ReGenerate-1 Uppsala...